- Home
- VOYA vs LEGN Comparison
VOYA vs LEGN Comparison
Compare VOYA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOYA
- LEGN
- Stock Information
- Founded
- VOYA 1975
- LEGN 2014
- Country
- VOYA United States
- LEGN United States
- Employees
- VOYA N/A
- LEGN N/A
- Industry
- VOYA Life Insurance
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- VOYA Finance
- LEGN Health Care
- Exchange
- VOYA Nasdaq
- LEGN Nasdaq
- Market Cap
- VOYA 6.7B
- LEGN 7.0B
- IPO Year
- VOYA 2013
- LEGN 2020
- Fundamental
- Price
- VOYA $71.95
- LEGN $39.70
- Analyst Decision
- VOYA Buy
- LEGN Strong Buy
- Analyst Count
- VOYA 12
- LEGN 12
- Target Price
- VOYA $82.55
- LEGN $79.50
- AVG Volume (30 Days)
- VOYA 1.0M
- LEGN 955.3K
- Earning Date
- VOYA 02-04-2025
- LEGN 03-10-2025
- Dividend Yield
- VOYA 2.50%
- LEGN N/A
- EPS Growth
- VOYA 13.84
- LEGN N/A
- EPS
- VOYA 6.17
- LEGN N/A
- Revenue
- VOYA $8,050,000,000.00
- LEGN $520,183,000.00
- Revenue This Year
- VOYA N/A
- LEGN $121.13
- Revenue Next Year
- VOYA $5.31
- LEGN $65.25
- P/E Ratio
- VOYA $11.92
- LEGN N/A
- Revenue Growth
- VOYA 9.55
- LEGN 122.96
- 52 Week Low
- VOYA $64.10
- LEGN $30.17
- 52 Week High
- VOYA $84.30
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- VOYA 49.06
- LEGN 64.82
- Support Level
- VOYA $72.56
- LEGN $34.36
- Resistance Level
- VOYA $76.02
- LEGN $36.39
- Average True Range (ATR)
- VOYA 2.16
- LEGN 1.67
- MACD
- VOYA 0.14
- LEGN 0.34
- Stochastic Oscillator
- VOYA 62.41
- LEGN 94.68
About VOYA Voya Financial Inc.
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.